| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 02/25/2010 | US20100047179 Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production |
| 02/25/2010 | US20100047178 Perylenequinone derivatives and uses thereof |
| 02/25/2010 | US20100047177 treating or preventing axonal degradation in neuropathic diseases in mammals; axonopathy; administering an agent that increases AMP activated kinase (AMPK), LKB1 and CaMKK beta acitvity in diseased and/or injured neurons and supporting cells in an amount effective to decrease axonal degeneration |
| 02/25/2010 | US20100047176 Method and Kit for Testing Stress Effects in Living Organisms |
| 02/25/2010 | US20100047175 Sincalide Formulations |
| 02/25/2010 | US20100047174 Aav capsid library and aav capsid proteins |
| 02/25/2010 | US20100047173 Methods for Using Optical Agents |
| 02/25/2010 | US20100047172 Use of bacterial beta-lactamase for in vitro diagnostics and in vivo imaging, diagnostics and therapeutics |
| 02/25/2010 | US20100047171 Fusion Proteins That Contain Natural Junctions |
| 02/25/2010 | US20100047170 Peptide Prodrugs |
| 02/25/2010 | US20100047168 Soluble Zcytor 11 Cytokine Receptors |
| 02/25/2010 | CA2734936A1 Transcutaneous organ function measurement |
| 02/24/2010 | EP2157101A1 HSP peptides and analogs for modulation of immune responses via antigen presenting cells |
| 02/24/2010 | EP2155786A2 Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label |
| 02/24/2010 | EP2155261A1 Sensory feedback-based method for determining the bioavailability of orally administered dietary supplements |
| 02/24/2010 | EP2155259A2 Methods for diagnosing diseases and evaluating treatments therefor using pet |
| 02/24/2010 | EP2155255A2 Compositions that include a hydrophobic compound and a polyamino acid conjugate |
| 02/24/2010 | EP2155254A2 Polymers conjugated with platinum drugs |
| 02/24/2010 | EP2155253A2 Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs |
| 02/24/2010 | EP2155215A1 A gold nanoparticle based protease imaging probes and use thereof |
| 02/24/2010 | EP1644732B1 Animal model for the analysis of tumor metastasis |
| 02/24/2010 | EP0837696B1 Improved delivery of diagnostic and therapeutic agents to a target site |
| 02/24/2010 | CN101657219A Novel cascade polymer complexes, method for their production and pharmaceutical agents containing the same |
| 02/24/2010 | CN101657218A Nanoparticle-based imaging agents for X-ray / computed tomography and methods for making same |
| 02/24/2010 | CN101657217A Methods for determining cancer resistance to histone deacetylase inhibitors |
| 02/24/2010 | CN101654479A Mammalian receptor proteins, agents, and methods relating thereto |
| 02/23/2010 | US7668587 Optical imaging of induced signals in vivo under ambient light conditions |
| 02/23/2010 | US7668586 In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease |
| 02/23/2010 | US7668582 Biopsy site marker |
| 02/23/2010 | US7666670 Animal model for the fast identification of pharmaceutical active compounds in vivo |
| 02/23/2010 | US7666424 Directed against a target antigen, cell culture to express, code the protein, for treating cancer |
| 02/23/2010 | US7666415 Production and use of novel peptide-based agents for use with bi-specific antibodies |
| 02/23/2010 | US7666393 Methods for assessing antiangiogenic agents |
| 02/23/2010 | US7666392 such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) for detecting angiogenesis in solid tumors; cyclic peptide based on 2,5,8,11,14-pentaoxo-1,4,7,10,13-pentaazacyclopentadecane ring having carboxymethyl, guanidine and radionuclide-containing side chains |
| 02/23/2010 | US7666391 Therapeutic treating breast cancer |
| 02/23/2010 | US7666390 DTPA derivatives and metal complexes thereof, and radiation source and contrast agent including the metal complexes |
| 02/23/2010 | CA2257852C Transgenic non-human mammals with progressive neurologic disease |
| 02/23/2010 | CA2198899C Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| 02/22/2010 | CA2676035A1 Biopsy marker delivery device |
| 02/18/2010 | WO2010018723A1 Liquid indigo carmine preparation |
| 02/18/2010 | WO2010018460A1 Fluorescent emulsion |
| 02/18/2010 | WO2010018230A2 Method for detecting dysplasia |
| 02/18/2010 | WO2010018222A1 Nanocrystal nano-emulsion |
| 02/18/2010 | WO2010018216A2 Fluorescent emulsion of indocyanine green |
| 02/18/2010 | WO2009156445A3 Use of cobalt ferrites as contrast agents for magnetic resonance |
| 02/18/2010 | WO2009146099A3 Contrast agents, methods for preparing contrast agents, and methods of imaging |
| 02/18/2010 | WO2009139972A3 Site specific fluorescence marking and contrast marker for same |
| 02/18/2010 | WO2009112488A4 Polyether polyol dendron conjugates with effector molecules for biological targeting |
| 02/18/2010 | WO2009106552A3 Contrast agents |
| 02/18/2010 | WO2009046281A3 Injectable particles |
| 02/18/2010 | US20100041868 Conserved neisserial antigens |
| 02/18/2010 | US20100041827 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly |
| 02/18/2010 | US20100041826 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly |
| 02/18/2010 | US20100041744 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| 02/18/2010 | US20100041082 Methods for determining the metabolism of sugars and fats in an individual |
| 02/18/2010 | US20100041075 Tuberculosis Diagnostic Test |
| 02/18/2010 | US20100040556 Carrier nanoparticles and related compositions, methods and systems |
| 02/18/2010 | US20100040555 Magnetic Nanoparticles Compositions and Uses Thereof |
| 02/18/2010 | US20100040554 Conjugates of photo-activatable dyes |
| 02/18/2010 | US20100040553 Spherical ferrite nanoparticle and method for production thereof |
| 02/18/2010 | US20100040552 Methods to evaluate glucocorticoid receptor agonists and antagonists for effects on neuron-like cells |
| 02/18/2010 | US20100040551 Animal Model of Central Neuropathic Pain and Methods of Making and Using the Same |
| 02/18/2010 | US20100040550 Radiolabelling methods |
| 02/18/2010 | US20100040549 Composition for Targeted Drug Delivery and Controlled Release |
| 02/18/2010 | US20100040548 High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds |
| 02/18/2010 | US20100040547 Dyes and precursors and conjugates thereof |
| 02/18/2010 | US20100040546 Biological targeting compositions and methods of using the same |
| 02/18/2010 | US20100040542 Chelator conjugates |
| 02/18/2010 | US20100040541 Structural Variants of Antibodies for Improved Therapeutic Characteristics |
| 02/18/2010 | US20100040537 antibodies that are wild-type, chimeric, CDR grafted and humanized; disease or disorder in which prostaglandin E2 activity is detrimental, such as cancer, atuoimmune diseases, inflammatory diseases |
| 02/18/2010 | DE102008039417A1 Mittel zum Nachweis und zur Behandlung von Prostatazellen Means for the detection and treatment of prostate cells |
| 02/18/2010 | CA2733994A1 Fluorescent emulsion |
| 02/18/2010 | CA2733959A1 Nanocrystal nano-emulsion |
| 02/18/2010 | CA2733942A1 Fluorescent emulsion of indocyanine green |
| 02/17/2010 | EP2153820A1 Liposome and method for producing liposome |
| 02/17/2010 | EP2153812A1 X-ray opaque infiltrant |
| 02/17/2010 | EP2152757A1 Functionalization of nanoparticles by glucosamine derivatives |
| 02/17/2010 | EP2152369A2 Use of fluoride-containing compounds for diagnostic purposes with the help of imaging processes |
| 02/17/2010 | EP2152320A2 Encapsulated contrast agents |
| 02/17/2010 | EP2152318A2 Uses and compositions for treatment of psoriasis and crohn's disease |
| 02/17/2010 | EP2152255A1 Ophthalmic formulations of amyloid- contrast agents and methods of use thereof |
| 02/17/2010 | EP2152167A1 Methods and systems for coupling and focusing acoustic energy using a coupler member |
| 02/17/2010 | EP1729818B8 Contrast agents for magnetic resonance imaging |
| 02/17/2010 | EP1263954B1 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/17/2010 | CN101652149A imaging probes |
| 02/17/2010 | CN101652148A Method for diagnosing disease using adenovirus harboring trans-splicing ribozyme by molecular imaging |
| 02/17/2010 | CN101648026A Sterilizing type medical ultrasonic coupling agent and preparation method thereof |
| 02/17/2010 | CN101648025A Method for preparing magnetic nano contrast agent and application thereof in pancreatic cancer magnetic resonance imaging |
| 02/17/2010 | CN101648024A Medicinal liquid preparation of glucose for OGTT and preparation method thereof |
| 02/16/2010 | US7664543 CT scanner for and method of imaging a preselected portion of the lower abdomen region of a patient |
| 02/16/2010 | US7663017 animal models having disrupted genes, used to test the immunogenicity of human vaccine candidates; drug screening |
| 02/16/2010 | US7662861 Compositions containing prodrugs of florfenicol and methods of use |
| 02/16/2010 | US7662857 Diagnostic agents for pancreatic exocrine function |
| 02/16/2010 | US7662387 administering a conjugate of antibody ( humanized, chimeric or constant region) and a drug such as fetoprotein/alpha-/, monomethyl auristatin E or monomethyl auristatin F to treat CD70-expressing cancer selected from a kidney tumor, a B cell lymphoma, a thymic carcinoma, and a nasopharyngeal carcinoma |
| 02/16/2010 | US7662383 Epitope bound by MAbs A, B, C or D, where MAbs A, B, C and D have given variable domains; chimeric or humanized for side effect reduction; polymerase chain reaction |
| 02/16/2010 | US7662374 Dual-specificity antibody having specificity for both an activated erbB2 receptor and erbB1 dimers, without significant affinity for monomeric EGFr that is not activate; specificity of the antibodies is due to their recognition and binding of activation epitopes; diagnosis, imaging and for treating tumor |
| 02/16/2010 | US7662362 Nanoparticulate probe for in vivo monitoring of tissue oxygenation |
| 02/16/2010 | US7662361 By treating a cancer with paclitaxel and a telomerase inhibitory agent, such as AZT, telomere damage induced resistance to paclitaxel is avoided |
| 02/16/2010 | CA2309154C Substituted porphyrins |
| 02/11/2010 | WO2010017546A1 Carbon nanotube based magnetic resonance imaging contrast agents |